# Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia

> **NCT01446055** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xuanwu Hospital, Beijing** · enrollment: 50 (estimated)

## Conditions studied

- Critical Limb Ischemia
- Peripheral Arterial Disease
- Buerger's Disease

## Interventions

- **DEVICE:** ResQ processed bone marrow sample
- **DEVICE:** Ficoll conventional cell processing method

## Key facts

- **NCT ID:** NCT01446055
- **Lead sponsor:** Xuanwu Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2011-10
- **Primary completion:** 2012-04
- **Final completion:** 2013-04
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-10-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01446055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01446055, "Safety and Efficacy Study of Autologous BM-MNC Processed by Two Methods for Treating Patients With Chronic Limb Ischemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01446055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*